What is the current valuation of the UK Radioligand Therapy Rlt Market?

The market valuation was 0.366 USD Billion in 2024. Read More

What is the projected market size for the UK Radioligand Therapy Rlt Market by 2035?

The projected valuation for 2035 is 0.9 USD Billion. Read More

What is the expected CAGR for the UK Radioligand Therapy Rlt Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 8.52%. Read More

Which companies are the key players in the UK Radioligand Therapy Rlt Market?

Key players include Novartis, Bayer, AstraZeneca, and Bristol-Myers Squibb. Read More

What are the primary applications of radioligand therapy in the UK market?

The primary applications include oncology, cardiology, neurology, and endocrinology. Read More

How does the market segment by end use in the UK Radioligand Therapy Rlt Market?

The market segments by end use include hospitals, diagnostic centers, and research institutions. Read More

What types of radioligands are utilized in the UK market?

The types of radioligands include alpha emitters, beta emitters, and Auger electron emitters. Read More

What are the common administration routes for radioligand therapy in the UK?

Common administration routes include intravenous, oral, and subcutaneous. Read More

Which diseases are primarily targeted by radioligand therapy in the UK?

The primary target diseases include prostate cancer, neuroendocrine tumors, and lymphoma. Read More

What is the growth outlook for the UK Radioligand Therapy Rlt Market?

The market appears poised for growth, with a projected increase to 0.9 USD Billion by 2035. Read More

UK Radioligand Therapy Market

ID: MRFR/Pharma/50329-HCR

200 Pages

Rahul Gotadki

Last Updated: March 28, 2026

UK Radioligand Therapy RLT Market Research Report By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Others) and By End User (Hospitals & Clinics, Diagnostic Centers, Others) - Growth & Industry Forecast 2025 To 2035

UK Radioligand Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)8.52%

2024 Market Size$ 0.37 Billion

2025 Market Size$ 0.4 Billion

2035 Market Size$ 0.9 Billion

Key Players

Novartis

Bayer

AstraZeneca

Bristol-Myers Squibb

Eli Lilly

Siemens Healthineers

Trends

Emergence of Targeted Therapies
Regulatory Advancements
Collaboration in Research and Development

Opportunities

Growing Incidence of Cancer
Increased Investment in Healthcare
Rising Awareness and Patient Advocacy

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiology
  3. 4.1.3 Neurology
  4. 4.1.4 Endocrinology
2. 4.2 Healthcare, BY End Use (USD Billion)
  1. 4.2.1 Hospitals
  2. 4.2.2 Diagnostic Centers
  3. 4.2.3 Research Institutions
3. 4.3 Healthcare, BY Type of Radioligand (USD Billion)
  1. 4.3.1 Alpha Emitters
  2. 4.3.2 Beta Emitters
  3. 4.3.3 Auger Electron Emitters
4. 4.4 Healthcare, BY Administration Route (USD Billion)
  1. 4.4.1 Intravenous
  2. 4.4.2 Oral
  3. 4.4.3 Subcutaneous
5. 4.5 Healthcare, BY Target Disease (USD Billion)
  1. 4.5.1 Prostate Cancer
  2. 4.5.2 Neuroendocrine Tumors
  3. 4.5.3 Lymphoma
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Siemens Healthineers (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 GE Healthcare (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Ipsen (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Lantheus Medical Imaging (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY APPLICATION
3. 6.3 UK MARKET ANALYSIS BY END USE
4. 6.4 UK MARKET ANALYSIS BY TYPE OF RADIOLIGAND
5. 6.5 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
6. 6.6 UK MARKET ANALYSIS BY TARGET DISEASE
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY END USE, 2026-2035 (USD Billion)
  3. 7.2.3 BY TYPE OF RADIOLIGAND, 2026-2035 (USD Billion)
  4. 7.2.4 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
  5. 7.2.5 BY TARGET DISEASE, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Radioligand Therapy Market Segmentation

UK Radioligand Therapy Market By Application (USD Billion, 2026-2035)

Oncology
Cardiology
Neurology
Endocrinology

UK Radioligand Therapy Market By End Use (USD Billion, 2026-2035)

Hospitals
Diagnostic Centers
Research Institutions

UK Radioligand Therapy Market By Type of Radioligand (USD Billion, 2026-2035)

Alpha Emitters
Beta Emitters
Auger Electron Emitters

UK Radioligand Therapy Market By Administration Route (USD Billion, 2026-2035)

Intravenous
Oral
Subcutaneous

UK Radioligand Therapy Market By Target Disease (USD Billion, 2026-2035)

Prostate Cancer
Neuroendocrine Tumors
Lymphoma

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”